Haplo-Cord HSCT for AML/MDS

This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (haploidentical engraftment versus cord blood engraftment) on clinical outcomes. By comparing the efficacy of haploidentical-cord blood transplantation in different subtypes of AML and MDS, this research will explore its unique advantages and comparative effectiveness relative to conventional transplantation strategies, so

Trial Details

NCT ID
NCT07588360
Phase
NA
Sponsor
Fujian Medical University Union Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • haplo-cord HSCT
  • Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age between 14 and 60 years, with no gender restriction.
  • Intermediate- or high-risk AML in first complete remission (CR1).
  • AML in second or subsequent complete remission (≥ CR2).
  • Relapsed or refractory AML.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →